Metastatic Breast Cancer
When to treat, delay, or omit breast cancer therapy in the face of COVID-19
Two groups have released recommendations for treating breast cancer patients during the pandemic.
CLEOPATRA: Pertuzumab has long-term benefit in HER2+ breast cancer
Adding pertuzumab to trastuzumab and docetaxel as first-line therapy for metastatic HER2-positive breast cancer reduced the risk of death by 31%...
HRQOL deteriorates after disease progression in metastatic cancer
The association between progression and global HRQOL was of greatest magnitude in lung and pancreatic cancer.
FDA approves neratinib in combination for metastatic HER2-positive breast cancer
Neratinib (NERLYNX) is approved for use in combination with capecitabine for adults with advanced or metastatic HER2-positive breast cancer who...
Metastatic breast cancer lesions immunologically depleted compared with primary
In an analysis of the immune microenvironment of breast cancer tissue samples, metastatic breast cancer lesions were relatively inert compared...
Lower CTC count IDs indolent MBC disease subset
A CTC count less than 5 per 7.5 mL of blood in MBC patients indicates an indolent disease subset, pooled data from two large cohorts show.
FDA expands indication for ribociclib for advanced breast cancer
Approval of the CDK 4/6 inhibitor was expanded to include the treatment of pre/perimenopausal women with HR-positive, HER2-negative, in...
FDA approves abemaciclib for advanced breast cancer
The indication for the CDK4/6 inhibitor includes treatment in combination with fulvestrant and as a single agent.
HER2 status differed between primary tumor and CTCs in 18.8% of women with MBC
The probability of HER2 status discordance decreased with increasing age, but increased with primary tumors that were hormone-receptor positive,...
VIDEO: Dr. William J. Gradishar shares breast cancer take-aways from ASCO 2017
Expert provides take-home messages on pertuzumab, PARP inhibitors, and CDK4/6 inhibitors.